BGIM
AKBA icon

Brandywine Global Investment Management’s Akebia Therapeutics AKBA Stock Holding History

Brandywine Global Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-89,760
Closed -$570K – 798
2019
Q4 		$570K Buy
89,760
+5,970
+7% +$28.4K ﹤0.01% 593
2019
Q3 		$329K Sell
83,790
-15,213
-15% -$65.2K ﹤0.01% 598
2019
Q2 		$480K Buy
99,003
+45,698
+86% +$260K ﹤0.01% 595
2019
Q1 		$437K Sell
53,305
-6,490
-11% -$44.5K ﹤0.01% 579
2018
Q4 		$331K Buy
+59,795
New +$468K ﹤0.01% 579

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Brandywine Global Investment Management's AKBA Position: Q1 2020 in Review

Brandywine Global Investment Management sold out of Akebia Therapeutics (AKBA) in Q1 2020, closing a stake of 89,760 shares — an estimated $570K sold.

Brandywine Global Investment Management first reported a position in AKBA in Q4 2018 and held it in 5 quarters. The position peaked at $570K in Q4 2019. 155 funds tracked by Wall St. Rank hold AKBA as of Q1 2020.

  • Brandywine Global Investment Management reported no remaining Akebia Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Brandywine Global Investment Management sold 89,760 Akebia Therapeutics shares in Q1 2020, an estimated $570K.
  • Brandywine Global Investment Management first reported a position in Akebia Therapeutics in Q4 2018 and held it in 5 quarters.
  • Brandywine Global Investment Management's Akebia Therapeutics position peaked at $570K in Q4 2019.
  • 155 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2020.

Based on Brandywine Global Investment Management's 13F filing for Q1 2020, filed 15 May 2020.